Oxurion NV — Director's Dealing 2023

Apr 14, 2023

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Leuven, BELGIUM, Boston, MA, US – April 14, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation¹ it has received a transparency notification as follows:

Oxurion received a transparency notification on April 12, 2023 from Atlas Special Opportunities LLC indicating that as of April 11, 2023, it held 26,728,439 shares of the then outstanding 632,659,186 shares, and therefore crossed above the threshold (3%) by virtue of acquisition of voting securities. See Annex 1

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forwardlooking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

________

Oxurion NV	US
Tom Graney	Conway Communications
Chief Executive Officer	Mary T. Conway
Tel: +32 16 75 13 10	mtconway@conwaycommsir.com
" tom.graney@oxurion.com
	ICR Westwicke
Michael Dillen	Christopher Brinzey
Chief Business Officer	Tel: +1 617 835 9304
Tel: +32 16 75 13 10	Chris.Brinzey@westwicke.com
michael.dillen@oxurion.com

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

FSMA	FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
1) Status of the notification
	Final
2) Issuer
	OXURION Name 0881-620-924 Identification number
3) Reason for the notification
	Acquisition or disposal of voting securities or voting rights		$\pm$
4) Notification by
	A person that notifies alone		$+$
	5) Persons subject to the notification requirement
	Name	Address (for legal entities)
	Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577
	6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
	Name	Address (for legal entities)
	persons referred to in Sections 5 and 6	Please continue entering the information in part II concerning the Part II
	7) Date on which the threshold is crossed
		05/04/2023 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
		$\ensuremath{\mathsf{3}}$
		If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

632,659,186 Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights % of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	7.055.741	26.728.439	$\Omega$	4.22%	0.00%
	TOTAL	26,728,439	o	4.22%	0.00%

Start with "groups" of holders. Add subtotals with $\Sigma$ , and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will b

$\pm$

B) Equivalent financial instruments After the transaction # of voting rights
that may be
acquired if the
instrument is
exercised Holders of equivalent
financial instruments Exercise period or
date Type of financial instrument Expiration date % of voting rights Settlement $\ddot{}$ TOTAL $\bullet$ $0.00%$ The totals will be updated once you have clicked on TOTAL (A & B) # of voting rights % of voting rights CALCULATE 26,728,439 4.22%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder	will cease to hold / will hold again	voting rights as of

13) Additional information

Done at New York
On		11/04/2024 (DD/MM/YYYY)
	Name & capacity Patrick Vance, proxyholder	Signature	-DocuSigned by Patrick Vance _________